Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • SAPIEN 3...

    SAPIEN 3 :Less-invasive heart valve implant outperforms surgery

    Written by supriya kashyap kashyap Published On 2016-04-04T11:12:00+05:30  |  Updated On 4 April 2016 11:12 AM IST
    SAPIEN 3 :Less-invasive heart valve implant outperforms surgery

    Chicago : A minimally invasive procedure to replace the aortic heart valve is superior to open surgery for patients with an intermediate risk of complications, according to a study that could pave the way for wider use of the approach.


    Patients who received the less-invasive implant had fewer strokes and a lower mortality rate after one year than those whose valve was replaced through open heart surgery, the Sapien 3 study showed.


    The procedure, called transcatheter aortic valve replacement (TAVR), is currently available only for patients considered unlikely to survive open heart surgery or at high risk for complications.


    The new data, presented Sunday at the American College of Cardiology meeting in Chicago, will be used to seek U.S. regulatory approval for Edwards Lifesciences' Sapien 3 valve in patients deemed at intermediate risk for complications with open heart surgery.


    "It seems likely that TAVR will become the new benchmark for the treatment of severe aortic stenosis in intermediate-risk patients," Dr. Vinod Thourani, professor at Emory University School of Medicine and a lead investigator for the study, said in an interview.


    TAVR involves threading the valve into place through blood vessels using a catheter. Medtronic Plc also sells TAVR systems in the United States.


    The Sapien 3 study found that 4.6 percent of patients who received Edwards' valve had a stroke and 7.4 percent died within a year of their procedure. Among surgery patients, 8.2 percent suffered a stroke and 13 percent died.


    Surgery resulted in less valve leakage, or aortic regurgitation, than TAVR, but few people in either group experienced the complication, which affected 1.5 percent of the TAVR patients, Thourani said.


    The Sapien 3 study compared 1,078 TAVR patients with outcomes for 944 patients who had open heart surgery in a related trial called Partner II. The Partner II study, presented on Saturday, showed Edwards' older-model Sapien XT valve was as effective as surgery in intermediate-risk patients.


    Edwards expects U.S. regulators to review data from both studies to approve an expanded indication for the Sapien 3 valve before the end of the year, Chief Executive Michael Mussallem said in an interview.


    "The only option up until now has been open surgery, which is very effective, but many patients would not opt for that," he said.


    Approval would more than double the pool of patients eligible for the catheter-based approach, Mussallem said.


    "We expect the treatment paradigm for intermediate-risk patients to change almost overnight and for the TAVR market to accelerate dramatically," J.P. Morgan analyst Michael Weinstein said in a note to clients Saturday. (Editing by Andrew Roche)

    Dr. Vinod ThouraniEdwards LifesciencesEmory University School of Medicineheart surgeryHeart ValveMichael WeinsteinSapien 3 studyTAVRtranscatheter aortic valve replacement
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok